| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S19380 R82274 |
Straub (Controls exposed to LTG) (Oxcarbazepine) (Epilepsy), 2026 | Speech or language disorder - ICD-10 codes: F80.xx (except F80.4), H93.25 - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
0.99 [0.68;1.44] C excluded (control group) |
35/660 175/3,273 | 210 | 660 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S19373 R82186 |
Straub (Controls unexposed, sick) (Oxcarbazepine) (Epilepsy), 2026 | Speech or language disorder - ICD-10 codes: F80.xx (except F80.4), H93.25 - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 0.99 [0.70;1.41] | 35/660 456/8,887 | 491 | 660 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12798 R48221 |
Meador (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 | Language Score in 2 years old children with the Bayley Scales of Infant and Toddler Development (BSID-III) | 3rd trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: Yes extrapolated (cont. endpoint) |
1.40 [0.49;4.02] excluded (control group) |
-/13 -/93 | - | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12799 R48222 |
Meador (Oxcarbazepine) (Controls unexposed, disease free), 2021 | Language Score in 2 years old children with the Bayley Scales of Infant and Toddler Development (BSID-III) | 3rd trimester | prospective cohort | unexposed, disease free | Adjustment: Yes extrapolated (cont. endpoint) | 1.36 [0.47;3.92] | -/13 -/87 | - | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10097 R36770 |
Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 | Visits to a speech therapist (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes Controls: mixed indications |
1.30 [0.70;2.50] excluded (control group) |
13/143 157/2,916 | 170 | 143 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9087 R31120 |
Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 | Health care utilization: Speech therapy (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.70 [1.00;2.90] | 13/143 72,012/1,710,441 | 72,025 | 143 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9939 R35727 |
Videman (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2016 | Griffiths Mental Developmental Scale - Hearing and speech (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) |
2.11 [0.38;11.63] excluded (control group) |
-/10 -/8 | - | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9940 R35733 |
Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 | Griffiths Mental Developmental Scale - Hearing and speech (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) | 9.58 [2.67;34.33] | -/10 -/59 | - | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.81 [0.89;3.66] | 72,516 | 826 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick) (Oxcarbazepine) (Epilepsy; 2: Oxcarbazepine) (Controls unexposed, disease free; 3: Oxcarbazepine) (Controls unexposed, NOS; 4: Oxcarbazepine) (Controls unexposed, disease free;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 9939, 10097, 12798, 19380